Audited Financial Results for the year ended March 31, 2025<BR> Recommendation of Dividend @ 10% on paid up capital of the company
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Samrat Pharmachem Limited reported audited standalone results for FY25 with revenue from operations of Rs. 28,586.05 lakhs, a modest 1.5% rise over FY24's Rs. 28,158.12 lakhs. Profit after tax jumped sharply to Rs. 711.22 lakhs from Rs. 216.26 lakhs in FY24, nearly tripling year-on-year, driven by lower material costs and improved operating margins. However, the standalone quarter (Q4 FY25) showed a loss of Rs. 39.92 lakhs versus a Rs. 139.53 lakh profit in Q4 FY24, and revenue in Q4 fell about 14% to Rs. 7,120.31 lakhs. The Board has recommended a 10% dividend (Rs. 1.00 per share on Rs. 10 face value), subject to shareholder approval at the 33rd AGM on September 25, 2025. Statutory auditors Shah & Savla LLP issued an unmodified (clean) opinion on the results.
Strong full-year profit growth and a 10% dividend are positive for shareholders, but the Q4 loss, sharp decline in operating cash flow (net cash used of Rs. 1,009 lakhs vs Rs. 941 lakhs generated last year), and near-depletion of cash balance (from Rs. 966.75 lakhs to Rs. 4.83 lakhs) raise concerns about working capital strain and short-term liquidity. Investors should weigh the strong annual earnings print against the weakening quarter-end momentum and cash position.